Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mini-FST for prediction of acute kidney injury progression in critically ill ICU patients
jRCT1051260186Recruiting
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of furosemide in acute kidney failure (AKF). Primary endpoint: Progression of AKI stage within 7 days after furosemide administration. Started Sep 2026; status: recruiting.
02
Drugs
furosemide
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on jRCT1051260186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051260186.